A multi-centre open-label randomised non-inferiority trial comparing watchful waiting to antibiotic treatment for acute otitis media without perforation in low-risk urban Aboriginal and Torres Strait Islander children (the WATCH trial): study protocol for a randomised controlled trial

被引：0

作者：

Penelope Abbott

Hasantha Gunasekera

Amanda Jane Leach

Deborah Askew

Robyn Walsh

Kelvin Kong

Federico Girosi

Chelsea Bond

Peter Morris

Sanja Lujic

Wendy Hu

Tim Usherwood

Sissy Tyson

Geoffrey Spurling

Markeeta Douglas

Kira Schubert

Shavaun Chapman

Nadeem Siddiqui

Reeion Murray

Keitha Rabbitt

Bobby Porykali

Cheryl Woodall

Tina Newman

Jennifer Reath

机构：

[1] Western Sydney University,School of Medicine

[2] University of Sydney,Discipline of General Practice

[3] Menzies School of Health Research,Indigenous Studies Research Network

[4] University of Queensland,Centre for Big Data Research in Health

[5] Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care (Inala Indigenous Health Service),Sydney Medical School Westmead

[6] Queensland Health,undefined

[7] University of Newcastle,undefined

[8] Queensland University of Technology,undefined

[9] University of NSW,undefined

[10] University of Sydney,undefined

[11] Awabakal Aboriginal Primary Health Care Centre,undefined

[12] Winnunga Nimmityjah Aboriginal Health Service,undefined

[13] Aboriginal and Torres Strait Islander Community Health Services,undefined

[14] Tharawal Aboriginal Corporation,undefined

来源：

Trials | / 17卷

关键词：

Otitis media; Acute otitis media; Aboriginal and Torres Strait Islander peoples; Indigenous population; Children; Antimicrobial agents; Randomised controlled trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Early stoppage of empirical antibiotic therapy at clinical improvement in paediatric leukaemia patients with high-risk febrile neutropenia (ESAT-HR-FN study): Study protocol of a single centre investigator initiated randomised open label non-inferiority trial
Kn, Santhosh Kumar
Chellapuram, Santhosh Kumar
Ganguly, Shuvadeep
Pushpam, Deepam
Giri, Rupak Kumar
Bakhshi, Sameer
[J]. HELIYON, 2024, 10 (16)
[42] Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial
Djimde, Moussa
Tshiongo, Japhet Kabalu
Muhindo, Hypolite Mavoko
Tinto, Halidou
Sevene, Esperanca
Traore, Maminata
Vala, Anifa
Macuacua, Salesio
Kabore, Berenger
Dabira, Edgard Diniba
Erhart, Annette
Diakite, Hamadoun
Keita, Mohamed
Piqueras, Mireia
Gonzalez, Raquel
Menendez, Clara
Dorlo, Thomas P. C.
Sagara, Issaka
Mens, Petra
Schallig, Henk
D'Alessandro, Umberto
Kayentao, Kassoum
[J]. BMJ OPEN, 2023, 13 (10):
[43] Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to Enterobacteriaceae (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferiority clinical trial
Eduardo Lopez-Cortes, Luis
Rosso-Fernandez, Clara
Nunez-Nunez, Maria
Lavin-Alconero, Lucia
Bravo-Ferrer, Jose
Barriga, Angel
Delgado, Mercedes
Lupion, Carmen
Retamar, Pilar
Rodriguez-bano, Jesus
[J]. BMJ OPEN, 2017, 7 (06):
[44] Effect of time restricted eating versus current practice in dietetics on glycaemic control and cardio-metabolic outcomes in individuals at risk of developing type 2 diabetes: Protocol for a multi-centre, parallel group, non-inferiority, randomised controlled trial
Charrouf, Rasha
Parr, Evelyn B.
Hutchison, Amy T.
Flint, Steve A.
Teong, Xiao Tong
Wittert, Gary
Vincent, Andrew D.
Brennan, Leah
Devlin, Brooke L.
Hawley, John A.
Heilbronn, Leonie K.
[J]. CONTEMPORARY CLINICAL TRIALS, 2024, 146
[45] Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
Bajpai, Jyoti
Kapu, Venkatesh
Rath, Sushmita
Kumar, Sravan
Sekar, Anbarasan
Patil, Priyanka
Siddiqui, Altaf
Anne, Srikanth
Pawar, Akash
Srinivas, Sujay
Bhargava, Prabhat
Gulia, Seema
Noronha, Vanita
Joshi, Amit
Prabhash, Kumar
Banavali, Shripad
Sarin, Rajiv
Badwe, Rajendra
Gupta, Sudeep
[J]. LANCET ONCOLOGY, 2024, 25 (02): : 246 - 254
[46] Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial
Adam G. Stewart
Patrick N. A. Harris
Mark D. Chatfield
Roberta Littleford
David L. Paterson
[J]. Trials, 22
[47] Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial
Stewart, Adam G.
Harris, Patrick N. A.
Chatfield, Mark D.
Littleford, Roberta
Paterson, David L.
[J]. TRIALS, 2021, 22 (01)
[48] Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial
Mauz-Koerholz, Christine
Landman-Parker, Judith
Balwierz, Walentyna
Ammann, Roland A.
Anderson, Richard A.
Attarbaschi, Andische
Bartelt, Jorg M.
Beishuizen, Auke
Boudjemaa, Sabah
Cepelova, Michaela
Claviez, Alexander
Daw, Stephen
Dieckmann, Karin
Fernandez-Teijeiro, Ana
Fossa, Alexander
Gattenloehner, Stefan
Georgi, Thomas
Hjalgrim, Lisa L.
Hraskova, Andrea
Karlen, Jonas
Kluge, Regine
Kurch, Lars
Leblanc, Thiery
Mann, Georg
Montravers, Francoise
Pears, Jean
Pelz, Tanja
Rajic, Vladan
Ramsay, Alan D.
Stoevesandt, Dietrich
Uyttebroeck, Anne
Vordermark, Dirk
Koerholz, Dieter
Hasenclever, Dirk
Wallace, William Hamish
[J]. LANCET ONCOLOGY, 2022, 23 (01): : 125 - 137
[49] Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
Richard Dillon
Shanna Maycock
Aimee Jackson
Sonia Fox
Sylvie Freeman
Charles Craddock
Catherine Thomas
Emma Homer
Jane Leahy
Anna Mamwell
Nicola Potter
Nigel Russell
Andrew Wei
Hans Beier Ommen
Claire Hemmaway
Steve Knapper
Lucinda Billingham
[J]. BMC Cancer, 22
[50] Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
Dillon, Richard
Maycock, Shanna
Jackson, Aimee
Fox, Sonia
Freeman, Sylvie
Craddock, Charles
Thomas, Catherine
Homer, Emma
Leahy, Jane
Mamwell, Anna
Potter, Nicola
Russell, Nigel
Wei, Andrew
Ommen, Hans Beier
Hemmaway, Claire
Knapper, Steve
Billingham, Lucinda
[J]. BMC CANCER, 2022, 22 (01)

← 1 2 3 4 5 →